Association Between C-Reactive Protein to Albumin Ratio and Left Ventricular Thrombus Formation Following Acute Anterior Myocardial Infarction

Cirakoglu O. F., Aslan A. O., YILMAZ A. S., Sahin S., Akyuz A. R.

ANGIOLOGY, vol.71, no.9, pp.804-811, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 71 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.1177/0003319720933431
  • Journal Name: ANGIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.804-811
  • Keywords: C-reactive protein to albumin ratio, inflammation, left ventricular thrombus, anterior myocardial infarction, 2013 ACCF/AHA GUIDELINE, CARDIOVASCULAR-DISEASE, UNIVERSAL DEFINITION, TASK-FORCE, ELEVATION, INFLAMMATION, MANAGEMENT, ECHOCARDIOGRAPHY, ERA
  • Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

Left ventricular thrombus (LVT) is associated with inflammatory response in survivors with anterior ST-elevation myocardial infarction (STEMI). The C-reactive protein to albumin ratio (CAR) has been proposed as a marker of inflammation. However, there is a lack of data with respect to the role of CAR in LVT development. We investigated the relationship between CAR and LVT development in patients with anterior STEMI treated percutaneously; 955 consecutive patients were enrolled and LVT was observed in 126 (13.2%) patients. Clinical, demographic, and laboratory parameters were recorded. The CAR was significantly higher in patients with LVT (12.6 [8.6-16.1] vs 18.1 [11.5-23],P< .001). Other independent predictors for LVT development were lower ejection fraction, the presence of left ventricular apical aneurysm, proximal left anterior descending lesion location, glycoprotein IIb/IIIa inhibitors treatment, >1 diseased arteries, higher total protein level, neutrophil count, and peak creatine kinase myocardial band activity. In conclusion, the CAR may be useful as a simple tool for predicting LVT development among survivors of anterior STEMI.